Enable AccessibilityEnable Accessibility

Partnerships as Catalysts for Innovation

Core to Takeda’s values is the belief in putting patients first and at the center of all we do, and a commitment to improving patient outcomes. The organization continuously strives to create new expectations of our medicines and of ourselves.  Supporting and championing patient and physician communities through new innovations and collaborative partnerships to advance care is a priority.


When we put patients at the center, it permeates our everyday and encourages broader thinking and perspective. This gives us the ability to explore innovation for generating data, inclusion of patients treated in real-world settings, and new multi-stakeholder partnerships that can drive solutions to improve patient care and provide long-term support.


Putting together the right partnerships that can be catalysts for innovation is key. This year’s annual meeting of the American Psychiatric Association (APA) fell at the beginning of Mental Health Awareness Month. Takeda sponsored the APA Mental Health Innovation Zone, which included hosting two panel sessions featuring some of our key collaborators. Participants discussed novel strategies to harness digital innovation for patient-clinician engagement and support, leading to improved treatment adherence, and better clinical outcomes in MDD. The expert panelists represented diverse stakeholders across the healthcare ecosystem and showcased the power of multi-stakeholder partnerships.


Key discussion themes centered around several of Takeda’s partnerships and leading initiatives, including:

  • Harnessing the power of data, predictive analytics machine learning, and patient support solutions to improve adherence and clinical outcomes
  • Exploring how digital technology can help enhance patient-provider engagement, progress communication and shared decision-making, and help improve adherence to treatment, resulting in improved outcomes for patients with MDD
  • Using mobile application-based technology to measure mood, cognition, patient-reported outcomes, and activity data, to enhance counseling related to adherence, provide additional support, and help patients engage with treatment, modify behaviors, and make informed decisions

Working with our partners on digital innovations in this space will continue to permeate efforts to accelerate our ability to do more for patients.


"Progress depends on having better real-world data earlier in the treatment pathway, and this is where digital technology may be able to bridge the gap,” said Maggie McCue, Clinical Science Director, Takeda US Medical Office. “These panel sessions provided a platform for Takeda to further demonstrate our leadership in neuroscience, and our understanding of how the right data and multi-stakeholder partnerships can drive innovative solutions to improve patient care, provide long-term support to patients with MDD, with the hope of improving outcomes."


In addition to the panel sessions, activity in the Innovation Zone also included a presentation on Lighter Blue, a multichannel disease awareness platform that uses social media to raise awareness of the symptoms of MDD.


Takeda’s presence at the APA Innovation Zone is one example of how, as an organization, we are seeking opportunities to drive important conversations among stakeholders in an effort to continue to advance patient care.